Combination pharmacotherapy for cardiovascular disease

Annals of Internal Medicine

Volumn 143, Issue 8, 2005, Pages 593-599

  Weintraub, William S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FOLIC ACID ANTAGONIST; SIMVASTATIN; STATINE DERIVATIVE; CARDIOVASCULAR AGENT;

CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG EFFICACY; HIGH RISK POPULATION; HUMAN; LOWEST INCOME GROUP; MINORITY GROUP; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; TREATMENT PLANNING; UNITED STATES; DRUG COMBINATION; ECONOMICS; HEALTH CARE COST; LIFESTYLE; SOCIOECONOMICS;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DEVELOPING COUNTRIES; DRUG THERAPY, COMBINATION; HEALTH CARE COSTS; HUMANS; LIFE STYLE; PATIENT COMPLIANCE; SOCIOECONOMIC FACTORS;

EID: 26944484371     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-143-8-200510180-00010     Document Type: Review

References (55)

1. Yach D, Leeder SR, Bell J, Kistnasamy B. Global chronic diseases [Editorial]. Science. 2005;307:317. [PMID: 15661976]
2. Glover MJ, Greenlund KJ, Ayala C, Croft JB. Racial/ethnic disparities in prevalence, treatment, and control of hypertension-United States, 1999-2002. MMWR. 2005;54:7-9.
3. Chronic Disease Notes and Reports. Accessed at www.cdc.gov/nccdphp/cdnr /cdnr_fall0403.htm on 8 September 2005.
4. American Heart Association. Heart Disease and Stroke Statistics-2005 Update. Dallas, TX: American Heart Association; 2005.
5. Green A, Christian Hirsch N, Pramming SK. The changing world demography of type 2 diabetes. Diabetes Metab Res Rev. 2003;I9:3-7. [PMID: 12592640]
6. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290:1884-90. [PMID: 14532317]
7. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-34. [PMID: 9673301]
8. Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J, et al. A potential decline in life expectancy in the United States in the 21st century. Obstet Gynecol Surv. 2005;60:450-452. [PMID: 15995561]
9. Levit K, Smith C, Cowan C, Lazenby H, Martin A. Inflation spurs health spending in 2000. Health Aff(Millwood). 2002;21:172-81. [PMID: 11900074]
10. Heffler S, Smith S, Won G, Clemens MK, Keehan S, Zezza M. Health spending projections for 2001-2011: the latest outlook. Faster health spending growth and a slowing economy drive the health spending projection for 2001 up sharply. Health Aff (Millwood). 2002;21:207-18. [PMID: 11900160]
11. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746-53. [PMID: 11723030]
12. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation. 2001;104:2855-64. [PMID: 11733407]
13. McGinnis MJ, Williams-Russo P, Knickman JR. The case for more active policy attention to health promotion. To succeed, we need leadership that informs and motivates, economic incentives that encourage change, and science that moves the frontiers. Health Aff (Millwood). 2002;21:78-93. [PMID: 11900188]
14. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419. [PMID: 12829553]
15. Smith R. The most important BMJ for 50 years? BMJ. 2003;326.
16. Rapid responses from BMJ.com. Accessed at http://bmj.bmjjournals.com/cgi /eletters/326/7404/1419 on 8 September 2005.
17. Shiffman S, Mason KM, Henningfield JE. Tobacco dependence treatments: review and prospectus. Annu Rev Public Health. 1998;19:335-58. [PMID: 9611623]
18. Law MR, Wald NJ, Morris JK, Jordan R. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427-31.
19. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9. [PMID: 7968073]
20. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22. [PMID: 12114036]
21. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOTLLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58. [PMID: 12686036]
22. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504. [PMID: 15007110]
23. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988;296:313-6. [PMID: 3125882]
24. Hennekens CH, Peto R, Hutchison GB, Doll R. An overview of the British and American aspirin studies [Letter]. N Engl J Med. 1988;318:923-4. [PMID: 3352678]
25. Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation. 1989;80:749-56. [PMID: 2676237]
26. Haan MN, Wallace R. Can dementia be prevented? Brain aging in a population-based context. Annu Rev Public Health. 2004;25:1-24. [PMID: 15015910]
27. Hanon O, Forette F. Prevention of dementia: lessons from SYST-EUR and PROGRESS. J Neurol Sci. 2004;226:71-4. [PMID: 15537524]
28. Etminan M, Gill S, Samii A. The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies. Pharmacotherapy. 2003;23:726-30. [PMID: 12820814]
29. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol. 2002;59:378-84. [PMID: 11890840]
30. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med. 2004;117:823-9. [PMID: 15589485]
31. Amarenco P, Labreuche J, Lavallée P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004;35:2902-9. [PMID: 15514180]
32. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry. 2005;62:217-24. [PMID: 15699299]
33. Cook NR Chae C, Mueller FB, Landis S, Saks AM, Hennekens CH. Mis-medication and under-ucilization of aspirin in the prevention and treatment of cardiovascular disease. MedGenMed. 1999:E1. [PMID: 11104403]
34. Eron JJ, Yetzer ES, Ruane PJ, Becker S, Sawyer GA, Fisher RL, et al. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. AIDS. 2000;14:671-81. [PMID: 10807190]
35. Connor J, Rafter N, Rodgers A. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ. 2004;82:935-9. [PMID: 15654408]
36. Grimm RH Jr, Black H, Rowen R, Lewin A, Shi H, Ghadanfar M, et al. Amlodipine versus chlorthalidone versus placebo in the treatment of stage I isolated systolic hypertension. Am J Hypertens. 2002;15:31-6. [PMID: 11824857]
37. Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmer-Shevlin N. Medication compliance: a healthcare problem. Ann Pharmacother. 1993;27:S-24. [PMID: 8400462]
38. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279:458-62. [PMID: 9600480]
39. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens. 1997;10:697-704. [PMID: 9234822]
40. Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165:1147-52. [PMID: 15911728]
41. Mahoney EM, Chu H. Cost-effectiveness analysis alongside clinical trials: statistical and methodologic issues. In: Weintraub WS, ed. Cardiovascular Health Care Economics. Totowa, NJ: Humana Pr; 2003:123-56.
42. Krumholz HM, Weintraub WS, Bradford WD, Heidenreich PA, Mark DB, Paltiel AD. Task force #2-the cost of prevention: can we afford it? Can we afford not to do it? 33rd Bethesda Conference. J Am Coll Cardiol. 2002;40:603-15. [PMID: 12204490]
43. Weintraub WS, Warner CD, Mauldin PD, Becker ER, Gomes D, Cook J, et al. Economic winners and losers after introduction of an effective new therapy depend on the type of payment system. Am J Manag Care. 1997;3:743-9. [PMID: 10169536]
44. Rose G. Strategy of prevention: lessons from cardiovascular disease. Br Med J (Clin Res Ed). 1981;282:1847-51. [PMID: 6786649]
45. Glasgow RE, McKay HG, Piette JD, Reynolds KD. The RE-AIM framework for evaluating interventions: what can it tell us about approaches to chronic illness management? Patient Educ Couns. 2001;44:119-27. [PMID: 11479052]
46. Piette JD, Heisler M, Wagner TH. Cost-related medication underuse among chronically ill adults: the treatments people forgo, how often, and who is at risk. Am J Public Health. 2004;94:1782-7. [PMID: 15451750]
47. Paluck EC, Green LW, Frankish CJ, Fielding DW, Haverkamp B. Assessment of communication barriers in community pharmacies. Eval Health Prof. 2003;26:380-403. [PMID: 14631610]
48. Kochanek KD, Murphy SL, Anderson RN, Scott C. Deaths: final data for 2002. Natl Vital Stat Rep. 2004;53:1-115. [PMID: 15587328]
49. Health disparities experienced by black or African Americans-United States. MMWR Morb Mortal Wkly Rep. 2005:54:1-3. [PMID: 15647722]
50. Racial/ethnic disparities in prevalence, treatment, and control of hypertension-United States, 1999-2002. MMWR Morb Mortal Wkly Rep. 2005;54:7-9. [PMID: 15647724]
51. Racial/ethnic and socioeconomic disparities in multiple risk factors for heart disease and stroke-United States, 2003. MMWR Morb Mortal Wkly Rep. 2005;54:113-7. [PMID: 15703691]
52. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199-206. [PMID: 12851274]
53. Centers for Disease Control and Prevention. QuickStats: Percentage of persons who lacked health insurance coverage for more than 1 year, by race/ethnicity-United States, January-June 2004. MMWR. 2005;54:75.
54. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-52. [PMID: 15364185]
55. Mulrow C, Kussmaul W. The middle-aged and older American: wrong prototype for a preventive polypill? [Editorial] Ann Intern Med. 2005;142:467-8. [PMID: 15767624]